Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial

Liraglutide at doses up to 1.8 mg in combination with OADs and/or basal insulin is approved for the treatment of T2D. The randomized, double-blind, placebo-controlled trial SCALE Diabetes (NCT01272232) investigated the efficacy and safety of liraglutide 3.0 mg, as adjunct to diet and exercise, for weight management in obese/overweight adults with T2D.